Literature DB >> 11939687

Selective serotonin reuptake inhibitor-induced rash: case report and review of the literature.

Tracie J Sannicandro1, Martha C Farrar, John S Markowitz.   

Abstract

Selective serotonin reuptake inhibitors (SSRIs) are one of the most frequently prescribed classes of drugs. Rashes induced by SSRIs seldom have been reported in the literature. Computerized MEDLINE and Current Contents searches yielded a report of two cases of rash induced specifically by paroxetine. We describe a patient who developed a rash that appeared on day 3 of treatment with oral paroxetine 20 mg/day. Her rash was morbilliform, pruritic, and generalized over the trunk and limbs, with some facial involvement. There was no palm or sole involvement. The patient reported that she had experienced a similar reaction to fluoxetine, which may suggest a drug class effect. The rash resolved within 2 days of drug discontinuation and treatment with oral diphenhydramine and topical hydrocortisone cream.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11939687     DOI: 10.1592/phco.22.7.516.33666

Source DB:  PubMed          Journal:  Pharmacotherapy        ISSN: 0277-0008            Impact factor:   4.705


  3 in total

1.  HTR7 Mediates Serotonergic Acute and Chronic Itch.

Authors:  Takeshi Morita; Shannan P McClain; Lyn M Batia; Maurizio Pellegrino; Sarah R Wilson; Michael A Kienzler; Kyle Lyman; Anne Sofie Braun Olsen; Justin F Wong; Cheryl L Stucky; Rachel B Brem; Diana M Bautista
Journal:  Neuron       Date:  2015-06-11       Impact factor: 17.173

2.  Possible cross-sensitivity between sertraline and paroxetine in a panic disorder patient.

Authors:  Praveen H Khairkar; Govind M Bang; Adarshlata B Singh; Prashant G Tiple
Journal:  Indian J Pharmacol       Date:  2010-04       Impact factor: 1.200

Review 3.  Itch and Psyche: Bilateral Associations.

Authors:  Radomir Reszke; Jacek C Szepietowski
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.